Form 4: Karyopharm Therapeutics CFO Lori Macomber Awarded Stock and Options

Karyopharm Therapeutics' CFO, Lori Macomber, received 160,000 restricted stock units and options to purchase 650,000 shares of common stock on January 31, 2025.

Summary

• Lori Macomber, the EVP, CFO & Treasurer of Karyopharm Therapeutics, was granted 160,000 restricted stock units (RSUs) and options to purchase 650,000 shares of common stock on January 31, 2025.
• The RSUs were awarded under the company's 2022 Inducement Stock Incentive Plan and will convert to common stock on a one-for-one basis.
• The RSUs vest in three equal annual installments starting January 31, 2026.
• The stock options have an exercise price of $0.6221 per share and expire on January 30, 2035.
• The options vest as to 25% of the shares on January 31, 2026, with the remaining 75% vesting in 36 equal monthly installments thereafter.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of executive compensation, which is generally viewed positively as it aligns management's interests with shareholders. There are no negative implications.

Positives

• The grant of stock and options to the CFO aligns her interests with those of the shareholders.
• The vesting schedule of the RSUs and options encourages long-term commitment from the CFO.

Industry Context

Stock and option grants are a common practice in the biotechnology industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option and RSU grants are standard practice for executive compensation in the biotech industry.
• The vesting schedule of the options and RSUs is typical, with a mix of time-based and performance-based vesting often used.
• The exercise price of the options is likely set at or near the market price of the stock at the time of the grant, which is a common practice.
• Companies like Amgen, Gilead, and Biogen also use similar equity-based compensation plans for their executives.

Stakeholder Impact

• Shareholders may view the equity grants positively as they incentivize the CFO to improve company performance.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Karyopharm Therapeutics, stock options, restricted stock units, executive compensation, insider trading, Lori Macomber, CFO, equity awards